# DASL-HiCaP (NCT04136353)

> Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04136353
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Sydney
- Conditions: Prostate Cancer
- Interventions: Darolutamide; Placebo oral tablet; Luteinizing Hormone-Releasing Hormone Analog; External Beam Radiotherapy
- Enrollment: 1100
- Primary outcome: Metastasis-free survival

## Commentary we found

- YouTube: 23
- Podcasts: 12
- X threads: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dasl-hicap-nct04136353

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04136353", "email": "<work email>"}; the inbox owner confirms by the emailed link.